Public Health England licensing offers

The Public Health England as an executive agency of the UK Department of Health. As a UK Government Organisation PHE brings together public health specialists from more than 70 organisations in the UK into a single public health service.

PHE is committed to ensuring that its capabilities and discoveries are effectively developed and exploited in order to benefit public health in the UK and globally and has considerable experience of forming partnerships with industry (both major companies and SMEs) and of commercialising its IP through licensing, forming joint ventures and creating spin out companies.

Here below a list of available technologies for licensing

Technologies available for licensing:

• Immunotherapeutics for C. difficile infection

Two polyclonal antibodies have undergone pre-clinical development: the first candidate, which is for parenteral administration to treat severe CDI, is ready to enter Phase I clinical trials; the second candidate is to be administered orally for prophylaxis/extended treatment of recurrent infection.

• Detection of nucleic acid mutations

A rapid method has been developed for detecting both known and previously unknown mutations (including base changes, deletions and insertions).

• Clostridium difficile vaccine antigens

These chemically modified Clostridium difficile peptides have enhanced immunogenicity and good

• Meningitis vaccines

technologies related to vaccines against Neisseria meningitidis, including high level expression of antigens in outer membrane vesicles. Candidate vaccines are also available.

• TB Vaccine antigens

several antigens that are associated with latent mycobacterium tuberculosis (TB) infection. They have demonstrated enhanced protection in model systems.

• Decontamination monitoring

Rapid biological indicators for monitoring decontamination processes.

• Rapid detection of mycobacteria

This is a rapid, simple, specific and highly sensitive assay to detect mycobacterium in sputum at levels as low as a single genome copy. It is an “on the spot” technique suitable for use in the field by non-specialist personnel.

• Drug Resistant TB Assay

This assay determines multi-drug resistant TB by genotype, rather than phenotype, so results can be generated within hours, with minimum manipulation of the live organism.

• M. genitalium detection assay

This highly sensitive assay provides a high degree of specificity for detection of M. genitalium and a very low incidence of false positives, compared to existing PCR tests. It also enables measurement of pathogen load and monitoring for the development of resistance.

• Neutron detector

a new neutron detector with enhanced sensitivity across a wide energy range.

• Next Generation Polio Vaccine

A series of stable, modified virus strains have been developed that provide good immunogenicity, whilst enabling simpler, safer production of inactivated polio vaccine (IPV).

• Crimean-Congo Haemorrhagic Fever Virus antigenic composition

A viral vector delivered vaccine to protect subjects against infection with Crimean-Congo Haemorrhagic Fever virus (CCHF).

Interested Japanese entities can contact the EU-Japan Centre here